NLS Pharmaceutics Auditor Resigns Amidst Business Acquisition

Ticker: NCEL · Form: 6-K · Filed: Sep 19, 2025 · CIK: 1783036

Nls Pharmaceutics LTD. 6-K Filing Summary
FieldDetail
CompanyNls Pharmaceutics LTD. (NCEL)
Form Type6-K
Filed DateSep 19, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: auditor-change, corporate-event, legal-compliance

TL;DR

NLS Pharma's auditor, Marcum, is out effective immediately due to an acquisition; new auditor needed ASAP.

AI Summary

NLS Pharmaceutics Ltd. was notified by its auditor, Marcum LLP, on September 17, 2025, that Marcum will resign immediately. This resignation is a result of CBIZ CPAs P.C. acquiring Marcum's attestation business on November 1, 2024. The company is seeking a new auditor.

Why It Matters

The sudden resignation of an auditor can raise concerns about the company's financial reporting and internal controls, potentially impacting investor confidence.

Risk Assessment

Risk Level: medium — Auditor resignations can signal underlying issues or create uncertainty regarding financial reporting, increasing risk.

Key Players & Entities

FAQ

When was NLS Pharmaceutics Ltd. notified of Marcum LLP's resignation?

NLS Pharmaceutics Ltd. was notified on September 17, 2025.

Why is Marcum LLP resigning as auditor for NLS Pharmaceutics Ltd.?

Marcum LLP is resigning because CBIZ CPAs P.C. acquired Marcum's attestation business.

When did the acquisition of Marcum's attestation business by CBIZ CPAs P.C. occur?

The acquisition occurred on November 1, 2024.

What is the effective date of Marcum LLP's resignation?

Marcum LLP's resignation is effective immediately upon notification on September 17, 2025.

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer providing information about the resignation of NLS Pharmaceutics Ltd.'s auditor.

Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 17.2 · Accepted 2025-09-19 16:02:03

Filing Documents

(a)(1)(v) of Regulation S-K)

Item 304(a)(1)(v) of Regulation S-K). EXHIBIT INDEX Exhibit No. 16.1 Letter from Marcum LLP addressed to the U.S. Securities and Exchange Commission dated September 19, 2025. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 19, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing